Home Clinical and Healthcare Professional Hub Clinical Research Publications Minimal acute toxicity from proton beam therapy for major salivary gland cancer

11 / 06 / 21

Minimal acute toxicity from proton beam therapy for major salivary gland cancer


Abstract

Introduction: Proton beam therapy (PBT) reduces normal organ dose compared to intensity-modulated radiation therapy (IMRT) for patients with major salivary gland tumors. It is not known whether this dosimetric advantage is clinically meaningful for reducing acute toxicity.

Methods: We evaluated treatment parameters and acute toxicity outcomes of patients with major salivary gland cancers enrolled on the Proton Collaborative Group REG001-09 trial (NCT01255748).

Results: One-hundred and five patients with a median age of 61 years were included. The majority had parotid (N = 90) versus submandibular gland (N = 15) tumors. The patients were treated across seven institutions in the United States between 2010 and 2017, most commonly in the postoperative setting (70.5%) although a minority were treated definitively (29.5%). Median PBT dose was 66.5 GyE in 33 fractions; only one patient was prescribed less than 50 GyE. Chemotherapy was given concurrently to 20%. Median follow-up was 14.3 months. Acute grade 2 or higher toxicity included nausea (1.5%), dysgeusia (4.8%), xerostomia (7.6%), mucositis (10.5%) and dysphagia (10.5%).

Conclusions: PBT should be strongly considered when ipsilateral radiation therapy is indicated for major salivary gland cancer based on a considerably lower incidence of acute grade 2 or higher toxicity in this analysis compared to historical IMRT outcomes.

Chuong M, Bryant J, Hartsell W, Larson G, Badiyan S, Laramore GE, Katz S, Tsai H, Vargas C. Minimal acute toxicity from proton beam therapy for major salivary gland cancer. Acta Oncol. 2020 Feb;59(2):196-200. doi: 10.1080/0284186X.2019.1698764. Epub 2019 Dec 5. PMID: 31805791.

*Please refer to the Terms and Conditions of this website when leaving the site and viewing third party content. 

Consultants we currently work with (head & neck)

Dr Russell Banner

Dr Russell Banner is a Consultant Clinical Oncologist based in South Wales. His undergraduate training was at Christ’s College, Cambridge...

Read more
Dr Russell Banner

Dr Eleanor Aynsley

Dr Aynsley graduated from Leeds Medical School in 1999. She did medical training in Durham, gaining MRCP in 2004. She...

Read more
Dr Eleanor Aynsley

Dr Muthiah Sivaramalingam

Dr Muthiah Sivaramalingam has been a consultant in Clinical Oncology since 2007 and has been Principal Investigator for many clinical...

Read more
Dr Muthiah Sivaramalingam

Dr Shanmugasundaram Ramkumar

Dr Ramkumar is a Consultant Clinical Oncologist specialising in non-surgical treatment of Head and Neck cancer, Skull Base Tumours and...

Read more
Dr Shanmugasundaram Ramkumar

Dr Josef Kovarik

Dr Josef Kovarik is an acting consultant clinical oncologist and a Lead of ENT Oncology at the Northern Centre for Cancer...

Read more
Dr Josef Kovarik

Dr Cheng Boon

Dr Cheng Boon is Consultant Clinical Oncologist at the Worcester Oncology Centre at Worcester Royal Hospital. He completed medical training...

Read more
Dr Cheng Boon

Cancer treatments we offer

The Rutherford Cancer Centres provide high-quality cancer care by offering access to innovative and advanced treatment techniques using leading technology.

Consultants we work with

We provide exceptional patient support from diagnosis through to treatment and recovery, with leading consultants available at our centres across the country.

Centres across the UK

The Rutherford Cancer Centres provide cancer treatments and other healthcare services across the UK with our centres designed to put the patient experience first.

Contact Us

Get in Touch

If you'd like to speak to us about any of the treatments we offer please don’t hesitate to get in touch. Call us on 0800 210 0402 or

Our Trusted Healthcare Partners